Overview

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Pembrolizumab